Chief Scientific Advisor to the Central Government Vijayaraghavan said on Friday that those who developed the Coronavirus vaccine in India would have to go through a rigorous evaluation process, which would not compromise them. Vijayaraghavan indicated by his statement that the vaccine developed by the Indian Council of Medical Research (ICMR) -India Biotech is unlikely to arrive by August 15.
Vijayaraghavan while addressing a web seminar at the New Delhi-based think tank ‘Vivekananda International Foundation’ said that any vaccine takes 28 days in the first phase of testing on humans and is followed by two more phase trials.
He further said that the country’s drug regulator has cleared the vaccine testing of Bharat Biotech and Zydus Cadila, therefore, the vaccine for India Biotech or Zydus Cadila will have to go through a rigorous evaluation process which will not compromise any kind. .
The ICMR wrote a letter to select medical institutions and hospitals aiming to introduce the indigenous Kovid-19 vaccine by 15 August, in collaboration with Bharat Biotech, to expedite the approval of the clinical trial for the developed ‘covicin’ vaccine.
Asked questions on ICMR’s letter, Vijayaraghavan said, ‘On July 10, the first phase of clinical trials has started, the probability of starting trials at the same time is less in all 12 places.
He said, ‘Suppose the trial starts at the same time, then there will be an injection in the first phase, then another injection after seven days and then it will be examined after 14 days and then the results will be considered before taking a decision. Which will take up to 28 days.
Vijayaraghavan said that there will be two more stages after the first phase of testing, so if we look at the time frame for a vaccine globally, it will take several months until the third phase of testing after the first phase.
Also Read: Samsung: ‘Galaxy Watch Active 2 4G’ launches Made in India smartwatch
Experts have cautioned against hastening the process of developing the Kovid-19 vaccine and emphasized that hastening to develop an anti-pandemic vaccine is not in line with globally accepted regulations.
